Celltrion Pharm Inc banner
C

Celltrion Pharm Inc
KOSDAQ:068760

Watchlist Manager
Celltrion Pharm Inc
KOSDAQ:068760
Watchlist
Price: 57 900 KRW -0.69%
Market Cap: ₩2.6T

P/OCF

29.7
Current
34%
Cheaper
vs 3-y average of 45

Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.

P/OCF
29.7
=
Market Cap
₩2.6T
/
Operating Cash Flow
₩86.4B

Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.

P/OCF
29.7
=
Market Cap
₩2.6T
/
Operating Cash Flow
₩86.4B

Valuation Scenarios

Celltrion Pharm Inc is trading below its 3-year average

If P/OCF returns to its 3-Year Average (45), the stock would be worth ₩87 866.81 (52% upside from current price).

Statistics
Positive Scenarios
2/4
Maximum Downside
-70%
Maximum Upside
+122%
Average Upside
14%
Scenario P/OCF Value Implied Price Upside/Downside
Current Multiple 29.7 ₩57 900
0%
3-Year Average 45 ₩87 866.81
+52%
5-Year Average 65.7 ₩128 281.55
+122%
Industry Average 15.3 ₩29 887.37
-48%
Country Average 9 ₩17 534.33
-70%

Forward P/OCF
Today’s price vs future operating cash flow

Not enough data available to calculate forward P/OCF

Peer Comparison

All Multiples
P/OCF
P/E
All Countries
Close
Market Cap P/OCF P/E
KR
Celltrion Pharm Inc
KOSDAQ:068760
2.6T KRW 29.7 66.2
US
Eli Lilly and Co
NYSE:LLY
820.3B USD 48.8 39.7
US
Johnson & Johnson
NYSE:JNJ
542.6B USD 22.1 25.8
CH
Roche Holding AG
SIX:ROG
248.4B CHF 13.7 20.1
UK
AstraZeneca PLC
LSE:AZN
216.7B GBP 19.7 28.1
CH
Novartis AG
SIX:NOVN
218.2B CHF 14.3 19.6
US
Merck & Co Inc
NYSE:MRK
272.8B USD 16.6 14.9
IE
Endo International PLC
LSE:0Y5F
244.4B USD 907.7 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 9.8 11.4
US
Pfizer Inc
NYSE:PFE
152.3B USD 13 19.6
US
Bristol-Myers Squibb Co
NYSE:BMY
116.3B USD 8.2 16.5
P/E Multiple
Earnings Growth PEG
KR
C
Celltrion Pharm Inc
KOSDAQ:068760
Average P/E: 26.2
66.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.7
32%
1.2
US
Johnson & Johnson
NYSE:JNJ
25.8
8%
3.2
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
28.1
25%
1.1
CH
Novartis AG
SIX:NOVN
19.6
14%
1.4
US
Merck & Co Inc
NYSE:MRK
14.9
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.4
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.6
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.5
16%
1

Market Distribution

Higher than 81% of companies in Korea
Percentile
81st
Based on 1 012 companies
81st percentile
29.7
Low
0.2 — 4.2
Typical Range
4.2 — 16.6
High
16.6 —
Distribution Statistics
Korea
Min 0.2
30th Percentile 4.2
Median 9
70th Percentile 16.6
Max 2 215 132.4

Celltrion Pharm Inc
Glance View

Market Cap
2.6T KRW
Industry
Pharmaceuticals

In the bustling world of pharmaceuticals, Celltrion Pharm Inc. has carved a niche for itself, leveraging innovation and strategic market positioning. Born out of South Korea, this dynamic player operates with a vision to transform the pharmaceutical landscape, particularly through its expertise in biosimilars and small molecule drugs. By focusing on cutting-edge research and development, Celltrion Pharm is able to produce high-quality, cost-effective alternatives to branded biologics, which are essential for treating diseases such as cancer and autoimmune disorders. With a comprehensive pipeline of biosimilar products, the company effectively taps into a growing demand, driven by global healthcare systems seeking cost-efficient therapeutics amidst rising healthcare expenditures. Celltrion Pharm's operational strategy extends beyond product innovation. It encompasses robust manufacturing infrastructure and a global distribution network that underscores its financial growth. By owning state-of-the-art production facilities, the company ensures both the scale and quality required to meet international benchmarks, which is pivotal in the highly regulated pharmaceutical industry. Furthermore, strategic alliances and partnerships bolster its market reach, ensuring that its products have strong footholds not just locally, but globally. Through these multifaceted endeavors—ranging from R&D to distribution—the company has positioned itself as a formidable force, achieving sustainable revenue streams by addressing critical healthcare needs and optimizing drug accessibility worldwide.

Intrinsic Value
25 822.63 KRW
Overvaluation 55%
Intrinsic Value
Price ₩57 900
C
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett